WEBINAR | Civica’s Plan for “Democratizing” Insulin is a Model for Other Healthcare Market Problems

Dan Liljenquist, Chief Strategy Officer, Intermountain Healthcare, and Board Chair, Civica Rx.  Less than four years after it was launched, Civica Rx, the not-for-profit with a mission to make essential, quality medicines affordable and available to everyone, now provides 60 sterile injectable medications to more than 1,500 U.S. hospitals, representing one-third of all licensed hospital beds. Most importantly, it is bringing stability to the previously volatile supply (and price) of certain generic drugs. In March 2022, Civica announced an ambitious and detailed plan to develop and commercialize insulin at prices dramatically lower than current, unsustainable market prices. Come learn from the lead architect of Civica how organizational models and solutions like Civica’s can lead to new markets, repairing old, seemingly intractable market failures.